Webinar Date/Time: Tue, Jun 11, 2024 10:00 AM EDT
This webinar will cover the advantages of a fully automated in-line lysis system with a closed single-use loop for process development. In addition to state-of-the-art mixing control, it can be configured to automatically and continuously process up to 10–50 kg of resuspended E. coli cells every 8 hours.
Register Free: https://www.biopharminternational.com/bp_w/alkaline-lysis
Event Overview:
Generally, methods applied for the isolation of plasmid DNA involve a cell lysis step with the addition of a strong base (alkaline lysis), neutralization, and precipitation to recover the target pDNA in solution from precipitated contaminating cell components (genomic DNA, proteins, and protein-nucleic acid complexes). Uncontrolled use of an alkaline solution will degrade target pDNA, which is also sensitive to mechanical stress. Furthermore, highly viscous solutions may cause local heterogeneities or require extensive mixing, both potentially degrading the target pDNA. This webinar will present a fully automated in-line lysis system with a closed single-use loop for process development up to a pilot scale in the GMP environment. With a state-of-the-art mixing control, it can be configured to automatically and continuously process up to 10–50 kg of resuspended cells per workday depending on the configuration.
Key Learning Objectives:
Who Should Attend:
Speaker:
Matevz Korenc
Product Manager
Sartorius BIA Separations
After receiving a PhD in Biochemistry, Matevz Korenc continued as a team leader in Knauf insulation, where he managed the analytical support and material development in the EMEA region. Matevz joined Sartorius BIA Separations in 2021 as a project manager and two years later became fully active in in-line lysis machine development and GMP implementation. He is also an acrobatic basketball performer, never found in his comfort zone.
Register Free: https://www.biopharminternational.com/bp_w/alkaline-lysis
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.